A detailed history of Advisor Shares Investments LLC transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Advisor Shares Investments LLC holds 1,301,978 shares of CRDL stock, worth $2.63 Million. This represents 0.41% of its overall portfolio holdings.

Number of Shares
1,301,978
Previous 1,189,978 9.41%
Holding current value
$2.63 Million
Previous $999,000 135.84%
% of portfolio
0.41%
Previous 0.23%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$0.88 - $2.06 $98,560 - $230,720
112,000 Added 9.41%
1,301,978 $2.36 Million
Q4 2023

Feb 13, 2024

SELL
$0.67 - $1.0 $10,592 - $15,810
-15,810 Reduced 1.31%
1,189,978 $999,000
Q3 2023

Nov 06, 2023

SELL
$0.76 - $1.19 $10,602 - $16,600
-13,950 Reduced 1.14%
1,205,788 $1.09 Million
Q2 2023

Aug 09, 2023

BUY
$0.45 - $0.97 $18,000 - $38,800
40,000 Added 3.39%
1,219,738 $1.09 Million
Q1 2023

May 09, 2023

BUY
$0.47 - $0.81 $37,105 - $63,947
78,948 Added 7.17%
1,179,738 $578,000
Q4 2022

Feb 14, 2023

BUY
$0.48 - $0.77 $528,379 - $847,608
1,100,790 New
1,100,790 $561,000
Q1 2021

May 11, 2021

SELL
$2.08 - $4.08 $725,439 - $1.42 Million
-348,769 Closed
0 $0
Q4 2020

Jan 25, 2021

BUY
$1.84 - $2.64 $113,459 - $162,790
61,663 Added 21.48%
348,769 $970,000
Q3 2020

Nov 12, 2020

BUY
$1.51 - $2.58 $65,839 - $112,493
43,602 Added 17.91%
287,106 $876,000
Q2 2020

Jul 14, 2020

BUY
$1.68 - $2.34 $55,497 - $77,299
33,034 Added 15.7%
243,504 $577,000
Q1 2020

May 13, 2020

BUY
$1.4 - $3.63 $24,906 - $64,577
17,790 Added 9.23%
210,470 $600,000
Q4 2019

Jan 22, 2020

BUY
$1.9 - $3.54 $366,092 - $682,087
192,680 New
192,680 $681,000

Others Institutions Holding CRDL

About Cardiol Therapeutics Inc.


  • Ticker CRDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 61,942,500
  • Market Cap $125M
  • Description
  • Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...
More about CRDL
Track This Portfolio

Track Advisor Shares Investments LLC Portfolio

Follow Advisor Shares Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Shares Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Advisor Shares Investments LLC with notifications on news.